Trial Profile

A Phase 1 Study of ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Mesutoclax (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions; Therapeutic Use
Sponsors InnoCare Pharma

Most Recent Events

17 Aug 2026 According to an InnoCare Pharma media release, company accelerating global trial of mesutoclax in combination with azacitidine for AML, with patients enrolled in the U.S. and Australia.
03 Jun 2026 Results presented in the InnoCare Pharma Media Release.
22 May 2026 According to an InnoCare Pharma media release, data from this trial presented at the 2026 ASCO Annual Meeting

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com